What is it?
What memantine is
1Memantine is a synthetic adamantane-derived prescription medicine that blocks NMDA receptors. Retail listings sometimes use nootropic language, while the main human evidence concerns a separate clinical population.
Names, aliases and forms
Mechanisms of action
NMDA receptor antagonism
14Memantine blocks the NMDA receptor channel in a moderate-affinity, uncompetitive manner. Receptor activity alone does not establish a consumer cognitive benefit.
Potential effects and evidence map
Clinical reviews find small, population-specific effects in moderate-to-severe Alzheimer-type dementia. Healthy cognitive enhancement is not established: small volunteer experiments have null cognitive outcomes or task-specific impairment, and clinical findings cannot supply a healthy-user benefit score.
Healthy memory enhancement is not established. Dementia trial findings do not quantify benefit for healthy adults.
Healthy attention enhancement is not established by the small volunteer evidence.
Receptor pharmacology does not establish general neuroprotection or long-term brain support in healthy adults.
Typical dosages and timing
This is the U.S. immediate-release prescription label range, including clinical titration, rather than an established dose for healthy nootropic use. Product-specific prescribing instructions and release formulations are separate from retail serving claims.
Timing & effect horizon
Label pharmacokinetics put the plasma concentration peak at 3-7 hours after oral dosing. This absorption timing does not establish the onset of a cognitive benefit.
A reliable healthy-user cognitive onset, single-dose effect duration and cycling schedule are not established. Plasma peak and half-life describe drug exposure. Clinical response and trial windows in dementia cannot define a healthy-user regimen.
Safety, side effects and risk profile
As of 2026-10-19, U.S. labeling and EMA information identify memantine products as prescription medicines. National supply and import rules differ.
Other NMDA antagonists and urine-alkalinizing drugs are explicit label cautions.
Memantine is substantially renally cleared and label dosing changes in severe renal impairment.
Dizziness and confusion can affect driving and other safety-sensitive tasks; EU information describes a minor-to-moderate driving influence.
Dizziness and vomiting caused one withdrawal after a single 20 mg dose in a small healthy-volunteer PK study; clinical labeling also lists dizziness and headache.
Constipation and vomiting are reported in clinical labeling; healthy-adult rates are not established.
U.S. labeling reports inadequate human pregnancy data and no human-milk data.
Long-term safety and cognitive benefit in healthy nootropic users are insufficiently characterized.
The U.S. label contains a lower dose target for severe renal impairment and cautions for severe hepatic impairment. These are individual prescribing considerations; they do not establish a healthy-user dose.
Dizziness, headache, confusion and constipation are the common adverse reactions in dementia-trial labeling. Their healthy-adult frequency cannot be inferred from those trials.
Renal clearance is sensitive to urine pH. The label warns that A higher urine pH state that can slow renal elimination of some medicines.Source can increase exposure; this can arise with certain medicines or clinical conditions.
EU product information describes a minor-to-moderate influence on driving and machine use. Dizziness or confusion can interfere with safety-sensitive activities.
Interactions and cautions
Labeling says combined use with other NMDA antagonists has not been systematically evaluated and should be approached with caution.
Labeling gives sodium bicarbonate and carbonic anhydrase inhibitors as examples that can shift urine pH and reduce memantine clearance. Alkaline urine can also occur in renal tubular acidosis or severe urinary-tract infections.
Combination safety is not established for arbitrary nootropic stacks. Known label cautions for other NMDA antagonists are described above; speculative stack effects should not be assumed from individual-drug data.
Legal and regulatory status
As of 2026-10-19, U.S. DailyMed labeling classifies these memantine hydrochloride tablet products as prescription drugs. A retail listing does not establish lawful nonprescription supply or importability.
As of 2026-10-19, EMA information describes Ebixa as a prescription medicine. Authorization, local supply, brand availability and import requirements must be distinguished for each country.
Practical buying and quality notes
- A price-comparison listing does not verify pharmacy authorization, prescription compliance, authenticity, strength or contaminant testing. Retail availability alone does not establish consumer suitability or local legality.1
- Clinical products commonly contain memantine hydrochloride. EMA product information distinguishes the hydrochloride amount from its memantine-base equivalent. Match the release formulation, stated strength basis and units per pack before comparing price per unit; a tablet listed under capsules needs its original label checked.4
FAQ
Is memantine a supplement?
1U.S. labeling and EMA information checked on 2026-10-19 describe prescription medicine products. Supplement-style retail marketing does not establish a lawful dietary-supplement classification.
Does memantine improve memory in healthy people?
13No broad benefit is established. A small placebo-controlled study in 16 healthy men used a single 30 mg dose, found no significant verbal or visuospatial memory benefit, and impaired a conditioning task. Its dose and size limit generalization.
What does the prescription dosage range mean?
1It describes immediate-release clinical labeling. It is not a validated healthy-user dose, and renal impairment or a different release formulation changes the prescribing context.
How long does memantine last, and is there a cycle?
1The long half-life describes elimination rather than the duration of a cognitive benefit. Healthy-user effect duration and a validated nootropic cycling schedule are not established.
References
- DailyMed. Memantine hydrochloride tablets prescribing information.
- DailyMed. Memantine hydrochloride tablet patient information and adverse reactions.
- European Medicines Agency. Ebixa EPAR overview.
- European Medicines Agency. Ebixa EPAR product information.
- European Medicines Agency. Axura EPAR scientific discussion.
- U.S. Food and Drug Administration. Namenda (memantine hydrochloride) oral solution clinical pharmacology and biopharmaceutics review. NDA 21-627. 2005.
- NHS. Common questions about memantine.
- electronic Medicines Compendium. Memantine Mylan 10 mg film-coated tablets Summary of Product Characteristics.
- Liu MY, Meng SN, Wu HZ, Wang S, Wei MJ. Pharmacokinetics of single-dose and multiple-dose memantine in healthy Chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. Clinical Therapeutics. 2008;30(4):641-653.
- McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database of Systematic Reviews. 2019.
- PubChem Compound Summary for CID 4054, Memantine.
- PubChem Compound Summary for CID 181458, Memantine hydrochloride.
- Schugens MM, Egerter R, Daum I, Schepelmann K, Klockgether T, Loeschmann PA. The NMDA antagonist memantine impairs classical eyeblink conditioning in humans. Neuroscience Letters. 1997;224(1):57-60.
- Johnson JW, Kotermanski SE. Mechanism of action of memantine. Current Opinion in Pharmacology. 2006;6(1):61-67.